EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
compare the efficacy and safety of TCbHP and EC-THP regimen in HER2-positive breast cancer patients
HER2 Positive Early Breast Cancer
DRUG: Docetaxel|DRUG: carboplatin|DRUG: Trastuzumab|DRUG: Pertuzumab|DRUG: Epirubicin|DRUG: cyclophosphamide
iDFS, invasive Disease Free Survival, 5 years
DRFS, distant relapse free survival, 5 years|OS, overall survival, 5 years|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability], Incidence of treatment-emergent adverse events adverse events according to CTCAE 5.0, through study completion, an average of 1 year
The objective of this study is to conduct a randomized controlled clinical study to compare the efficacy and safety of TCbHP and EC-THP regimen in HER2-positive breast cancer patients, so as to further optimize adjuvant chemotherapy regimen for breast cancer.